+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 24 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
R

Actively Recruiting

Researchers are studying the safety and effectiveness of RTN-001, a modified release drug, in adults aged 18 to 75 years with uncontrolled and resistant hypertension, defined as systolic blood pressure SBP of 135 mm Hg or higher and diastolic blood pressure DBP of 80 mm Hg or higher. This Phase 2b trial is randomized, double-blind, and involves multiple centers. The study includes three main periods Screening, Run-in, and Treatment. During the trial, about 280 eligible participants will be randomly assigned equally into four groups to receive one of three doses of RTN-001 15 mg, 30 mg, or 45 mg or a matching placebo. The treatment lasts for 12 weeks. After the treatment period ends, participants will have an off-treatment follow-up visit two weeks later to assess their condition. Participants will be involved in various assessments throughout the study, including blood pressure measurements taken at multiple time points during and after treatment. Researchers will monitor changes in systolic and diastolic blood pressure using office measurements, central blood pressure readings, and ambulatory monitoring. Safety and efficacy will be evaluated through these repeated measures, and adherence to the study drug will be tracked. The total participation includes screening, run-in, treatment, and follow-up visits spanning several months.

Age: 18Years - 75YearsAll GendersPhase 2
44 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
P

Actively Recruiting

Researchers are evaluating the efficacy of selnoflast compared with a placebo in adults with atherosclerosis who are at high risk for major adverse cardiovascular events while already receiving standard-of-care therapy. This Phase IIa trial aims to assess how selnoflast influences vascular inflammation and other related outcomes in this population. Participants are randomly assigned to receive either selnoflast or a placebo, both taken orally twice a day for 12 weeks. The study includes careful monitoring of pharmacodynamics and pharmacokinetics. The main comparison focuses on changes in vascular inflammation as measured by specific imaging techniques over the 12-week treatment period. During the trial, participants will undergo assessments including specialized imaging scans to measure vascular inflammation, blood tests to track drug levels and safety, and monitoring for adverse events. The primary outcome is the change in target-to-background ratio in diseased vessels from baseline to week 12 in participants with elevated inflammation markers. Safety and other secondary outcomes are also evaluated. The total study duration extends up to approximately 22 weeks to cover treatment and follow-up assessments.

Age: 18Years +All GendersPhase 2
25 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.

Age: 5Years - 17YearsAll GendersPhase 3
104 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
P

Actively Recruiting

Researchers are evaluating CRD-4730, a calciumcalmodulin-dependent protein kinase II CaMKII inhibitor, in adults with heart failure with reduced ejection fraction HFrEF. This Phase 2, global, multi-center trial aims to assess the safety, tolerability, and effectiveness of CRD-4730 alongside guideline-directed medical therapy. Participants have chronic heart failure with a reduced heart pump function and are classified as New York Heart Association NYHA class II to III. Participants are randomly assigned to one of four groups to receive either one of three doses of CRD-4730 or a matching placebo. The study drug or placebo is given orally twice daily for a treatment period of 24 weeks. This double-blind trial ensures that neither participants nor researchers know which treatment is administered during the study. During the trial, participants undergo assessments including heart function tests, blood biomarker measurements, and questionnaires at baseline, mid-treatment week 12, and after 24 weeks of treatment. The main outcome measured is the change from baseline in a composite score at 24 weeks. Safety and response are monitored throughout, with total participation lasting about six months.

Age: 18Years - 85YearsAll GendersPhase 2
2 locations
R

Actively Recruiting

Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
63 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of the investigational drug CNP-103 in people aged 12 to 35 who have recently been diagnosed with Stage 3 Type 1 Diabetes within the last 6 months. This Phase 1b2a trial aims to understand how CNP-103 works and its effects in this population over about 393 days. Participants will receive three intravenous doses of CNP-103 at varying amounts 100 mg, 300 mg, or 600 mg on Days 1, 8, and 90. The study includes an initial Screening Period lasting 28 days, followed by a 90-day Treatment Period with dosing, and then a Post-Dose Evaluation phase lasting 275 days to monitor participants after treatment. Dosing for the Expansion Cohort will be based on results from the earlier Escalation Phase. During the study, participants will undergo assessments including safety and immune safety monitoring from Day 1 through Day 365. Researchers will collect data on how participants tolerate the treatment, any side effects, and immune responses. Participants will be monitored regularly throughout the nearly 13-month study period, including visits for drug administration, laboratory tests, and evaluations to measure the study outcomes and ensure safety.

Age: 12Years - 35YearsAll GendersPhase 1Phase 2
45 locations

1-10 of 24

1